Previous Article | Next Article 
Journal of Virology, April 2001, p. 3731-3739, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3731-3739.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Palindromic Sequence Plays a Critical Role in Human
Foamy Virus Dimerization
Dionne
Cain,
Otto
Erlwein,
Andrew
Grigg,
Rebecca A.
Russell, and
Myra O.
McClure*
Department of G.U. Medicine and Communicable
Diseases, Jefferiss Research Trust Laboratories, Wright-Fleming
Institute, Imperial College School of Medicine at St. Mary's, London
W2 1PG, United Kingdom
Received 27 June 2000/Accepted 26 January 2001
 |
ABSTRACT |
The retroviral RNA genome is dimeric, consisting of two identical
strands of RNA linked near their 5' ends by a dimer linkage structure.
Previously it was shown that human foamy virus (HFV) RNA transcribed in
vitro contained three sites, designated SI, SII, and SIII, which
contributed to the dimerization process (O. Erlwein, D. Cain, N. Fischer, A. Rethwilm, and M. O. McClure, Virology 229:251-258,
1997). To characterize these sites further, a series of mutants were
designed and tested for their ability to dimerize in vitro. The primer
binding site and a G tetrad in SI were dispensable for dimerization.
However, a mutant that changed the 3' end of SI migrated slower on
nondenaturing gels than wild-type RNA dimers. The sequence composition
of the SII palindrome, consisting of 10 nucleotides, proved to be
critical for in vitro dimerization, since mutations within this
sequence or replacement of the sequence with a different palindrome of
equal length impaired in vitro dimerization. The length of the
palindrome also seems to play an important role. A moderate extension
to 12 nucleotides was tolerated, whereas an extension to 16 nucleotides
or more impaired dimerization. When nucleotides flanking the palindrome
were mutated in a random fashion, dimerization was unaffected. Changing
the SIII sequence also led to decreased dimer formation, confirming its
contribution to the dimerization process. Interesting mutants were
cloned into the infectious molecular clone of HFV, HSRV-2, and were
transfected into BHK-21 cells. Mutations in SII that reduced
dimerization in vitro also abolished virus replication. In
contrast, constructs containing mutations in SI and SIII replicated to
some extent in cell culture after an initial drop in viral replication.
Analysis of the SIM1 mutant revealed reversion to the wild type but
with the insertion of an additional two nucleotides. Analysis of
cell-free virions demonstrated that both replication-competent and
replication-defective mutants packaged nucleic acid. Thus, efficient
dimerization is a critical step for HFV to generate infectious virus,
but HFV RNA dimerization is not a prerequisite for packaging.
 |
INTRODUCTION |
Foamy viruses (spumaviruses) are a
subfamily of the family Retroviridae. Although they have a
similar genomic structure to other retroviruses and replication is
characterized by reverse transcription and provirus integration
(17, 53), the foamy virus life cycle is quite divergent
from that of other retroviruses (reviewed in reference
38). For example, expression of the Pol protein differs in
that it is expressed from its own spliced mRNA rather than as a Gag-Pol
fusion protein (16, 61), both Gag and Env proteins are
needed for particle release (2, 21, 50), and vectors based
on foamy virus sequences need nucleotides in the pol open
reading frame (ORF) in addition to nucleotides in the 5' end for
transduction (19, 28, 58). Atypically for retroviruses,
but like hepadnaviruses, reverse transcription is a late event in the
human foamy virus (HFV) life cycle, resulting in a considerable number
of cell-free virions containing full-length infectious DNA (38,
42, 61).
The retroviral genome consists of two identical copies of RNA
associated noncovalently at the 5' ends by a dimer linkage sequence (DLS) (3, 32, 44). The mechanism of dimerization is still not fully understood, although two models have been suggested. The
kissing-loop model, first proposed for human immunodeficiency virus
type 1 (HIV-1), involves a palindromic sequence in a hairpin-loop structure called the dimer initiation sequence. It was proposed that
the palindromic sequence initiates dimerization through a Watson-Crick
base pairing to form an immature RNA dimer (27, 34, 49,
55). This mechanism has also been proposed for avian leukosis
sarcoma virus (23), HIV-2 (12), simian
immunodeficiency virus (12), and murine leukemia virus
(MLV) (22, 26, 43) and may represent a common retroviral
dimerization mechanism. Following particle release and protein
maturation, the nucleocapsid protein is thought to mediate dimer
maturation through conformational changes resulting in a more extensive
and stable dimer (14, 20, 24).
Alternatively, purine-rich motifs or guanine stretches may be involved
in dimerization through the formation of purine-base tetrads stabilized
by monovalent cations (1, 41, 56). In fact, G-rich
sequences are important for the dimerization of Moloney murine sarcoma
virus RNA (39). For other retroviruses, however, mutation
of the purine-rich motifs indicates that they are not essential for
dimerization (4, 6, 30, 54).
Conservation of RNA dimerization suggests that the process is
biologically important in the virus life cycle. This is supported by
the fact that HIV-1 DLS mutations lead to replication defects in vivo,
particularly in packaging (13, 36, 48). Moreover, the DLS
is located in a region of the genome that also encodes important
regulatory features, such as the primer binding site (PBS), the major
splice donor, the gag start codon, and cis-acting sequences for packaging. Thus, RNA dimerization may play a role in
reverse transcription, translation, and encapsidation of viral genomic RNA.
Dimerization was initially studied using short RNA sequences
transcribed in vitro (8, 14, 51). More recently, the
dimerization of HIV-1 has been studied in vivo (5, 27, 36,
48). While the kissing stem-loop is crucial for in vitro
dimerization of both MLV and HIV-1, it is involved in, but not
essential for, viral replication in vivo (5, 13, 22, 27,
48).
It was recently demonstrated that three sites (SI, SII, and SIII) are
involved in the in vitro dimerization of HFV RNA (18). These sites were located within a 159-nucleotide RNA fragment at the 5'
end of the genome. SI overlaps the PBS, SII contains the palindromic
sequence UCCCUAGGGA, and SIII flanks the start codon of the
gag ORF. In the present study, mutations were introduced into SI, SII, and SIII and the mutated RNA was tested for its ability to dimerize in vitro. Interesting mutations were also introduced into the infectious molecular clone of HFV, HSRV-2 (52). Analysis of protein expression and virus titer
revealed that mutations that reduced dimerization in vitro also
inhibited virus spread in cell culture, indicating the importance of
the dimerization process in the virus life cycle. When these mutants were analyzed for their nucleic acid content, it was found that they
all could package the viral genome. These data confirm that the DLS
plays an important role in the virus life cycle but indicate that at
least in the case of HFV, dimerization is not a prerequisite for packaging.
 |
MATERIALS AND METHODS |
Cell lines.
The baby hamster kidney (BHK-21) cell line and
its derivative, FAB (59), were cultured in Dulbecco's
modified Eagle's minimal essential medium supplemented with 5% fetal
calf serum, 25,000 U of penicillin per ml, and 250 µg of streptomycin
per ml. FAB cells are BHK-21 cells containing a single integrated copy
of the
-Gal gene under the control of the HFV long terminal repeat promoter. BHK/Bel-1 cells (7) were cultured in the same
medium containing G418 to a final concentration of 0.5 µg/µl.
Plasmid construction.
All cloning was done using standard
procedures. Plasmids for directing expression of the HFV dimerization
region were constructed using the pSPT322-950 vector previously
described (18), which was used to generate in vitro
RNA transcripts. These mutants are depicted in Table
1. Several SI mutants (SIM1, SIM2, SIM3,
SIM4) and SII mutants (SIIM1, SIIM2, SIIM3, SIIM4) were constructed by
ligating annealed complementary oligonucleotides (0.5 nmol) containing
the required mutations into pSPT322-950 digested with MunI
(position 346 of the viral RNA) and StyI (position 398). SIM5 was constructed by deleting the sequences between MunI
(position 342) and StyI (position 398), resulting in a 51-bp
deletion. SIM6 was constructed by deleting the sequences between
HpaI (position 360) from SIM3 and StyI (position
402), resulting in a 38-bp deletion. The mutant SIIM5 was constructed
by digesting pSPT322-950 with StyI (position 398) and
XhoI (position 946). A 5' primer complementary to positions
398 to 430 of the proviral DNA but containing the nucleotide changes
CCTCC to TTCTT (406 to 410) and a 3' primer complementary to positions
946 to 910 (containing an XhoI site at the 3' end) were used
to amplify a 548-nucleotide fragment using standard PCR techniques
(18). The resulting DNA fragment was inserted into the
vector pSPT322-950 to create SIIM5. Constructing SIIM6 required a
two-step cloning procedure. DNA was amplified from positions 406 to 946 and inserted into pSPT322-950 via EcoRI and SacI.
The resulting PCR product was inserted into the pSPT322-950 vector via
EcoR1 and Sac1 restriction sites. A second PCR
fragment was amplified from positions 319 to 395 and joined to the
intermediate construct via EcoRI and NaeI sites
to create S11M6. Construction of SIIM7 required a two-step cloning
procedure. First, sequences after the SII palindrome (positions 406 to
946) were PCR amplified, changing the palindrome into a
BstBI site (TTCGAA), and the amplicon was
inserted into pSPT322-950. Second, the sequences upstream of the
palindrome (319 to 395) were PCR amplified. SIIM7 was then created by
joining the two PCR products via the BstBI site. SIIM8, which changed the five nucleotides 3' to the palindrome, was
constructed by annealing oligonucleotides (positions 399 to 482)
containing the mutated nucleotides and inserting them into the
pSPT322-950 vector.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Illustration of the mutations in SI, SII, and SIII
together with their dimerization (in vitro), viral replication, and
RNA packaging (in cell culture) propertiesa
|
|
To construct SIIIM1, sequences from positions 461 to 946 were amplified
by PCR and the resulting DNA fragment was inserted into pSPT322-950 via
StyI and XhoI sites. Subsequently, annealed oligonucleotides spanning the sequences from positions 399 to 457 were
included. To construct SIIIM2, annealed oligonucleotides spanning from
positions 399 to 482 containing the desired changes were cloned into
the vector pSPT322-950. The resulting constructs containing the
mutations were confirmed by sequence analysis. For all constructs, DNA
was digested with MboII to generate mutant RNA up to
position 480 in order to test in vitro dimerization.
Transfer of mutations into pHSRV-2.
In the first instance,
the pHSRV-2 mutants SIM1, SIIM2, SIIM4, SIIM6, and SIIM7 were produced
by using pUC19 (Boehringer Mannheim) as an intermediate vector. A
fragment of pHSRV-2 from the KpnI site (DNA position 2) to
the PstI site (position 2973) was amplified using the Expand
High Fidelity PCR system (Boehringer Mannheim) and was cloned into
plasmid pUC19, giving pUC19/HSRV-2. This fragment contains the long
terminal repeat, the leader sequence, and some gag sequence.
Second, the mutated sequence was inserted into the pUC19/HSRV-2 vector
via EcoRV and MfeI sites. Finally, the mutated HSRV-2 sequence was transferred from pUC19 into the wild-type pHSRV-2
via KpnI and SwaI (position 2867) sites. To
construct pHSRV-2/SIIM8, a PCR-amplified sequence downstream of the SII palindrome (positions 1241 to 2891) was exchanged for the
KpnI/SwaI fragment of pHSRV-2 to produce an
intermediate construct. A PCR-amplified sequence upstream of the SII
palindrome (positions 2 to 1233) containing an XcaI site at
the 3' end was then ligated into the intermediate vector via
KpnI and SmaI sites. The mutant SIIIM2 was
constructed by PCR amplifying a fragment of pHSRV-2 from position 1274 to position 2915. The PCR product was inserted as a
KpnI/SwaI fragment into pHSRV-2, with the
env sequences between NdeI and NheI
deleted. Proviral sequences upstream of SIII from position 2 (KpnI site) to position 1271, incorporating an
AseI site at the 3' end, were PCR amplified and cloned into
the pUC19 cleaved with KpnI and NdeI. Finally,
the mutated sequences in SIII were inserted into pHSRV-2 as a
KpnI/PacI fragment to generate SIIIM2. The
resulting constructs containing the mutations were confirmed by
sequence analysis.
Analysis of mutants in cell culture.
All transfections were
carried out using the Calcium Phosphate Mammalian Transfection Kit
(Promega) using a total of 10 µg of plasmid DNA per 2 × 105 BHK-21 or BHK/Bel-1 cells. Cultures were passaged on
days 2, 7, and 10 posttransfection (p.t.), supernatant fluid (200 µl) was removed on days 2, 3, 5, 6, 7, 8, 9, 10, 13, and 14, and then the
supernatant was stored at
70°C. Reverse transcriptase (RT) activity
in the supernatant was assayed as described below. From supernatant
(1.5 ml) taken on days 3, 6, and 14, virus titer was assayed by
end-point dilution and by
-galactosidase staining of FAB cells
(59). Infected cells were analyzed for viral protein expression on days 2, 7, and 14, as described below. On day 14, DNA was
extracted from 106 cells to analyze the constructs by PCR,
restriction enzyme digestion, and sequencing (ABI Prism dRhodamine dye
terminator ready reaction kit; Perkin Elmer).
Analysis of the virions.
For RNase protection assays and
Western blotting, 106 BHK/Bel-1 cells (7) were
transfected in quadruplicate, each with 10 µg of the respective
mutant DNA. Two days after transfection, the supernatant from the four
flasks was pooled and concentrated using Centricon columns (Amersham)
and virus particles were pelleted through a 20% sucrose cushion in an
Optima TLX ultracentrifuge (Beckman) for 2 h at 50,000 rpm. The
pellet was resuspended in 50 µl of H2O, and 10 µl was
used for Western blotting to detect viral antigens by using human
antiserum (a gift from A. Rethwilm, University of Dresden, Dresden,
Germany). The nucleic acids were extracted from the remaining 40 µl
using the total RNA isolation kit (Qiagen) according to the
manufacturer's instructions. Gag-specific anti-sense RNA was generated
by linearizing plasmid pSPT322-950 (18) with
EcoRV and transcribing it with T7 polymerase in the presence
of 32P (Amersham). This resulted in RNA which was
complementary to gag ORF sequences 950 to 703 (protecting a
fragment of 248 nucleotides) relative to the start site of
transcription. A total of 70,000 cpm were used in the RNase protection
assay (RPA) using the RPA kit II (Ambion), which was carried out
according to the manufacturer's instructions.
RT assay.
RT activity was assayed by the colorimetric C-type
RT assay (Cavidi Tech AB) (15, 40). Briefly, polyadenylic
acid [poly(A)] covalently coupled to the wells of a 96-well
microtiter plate constituted the template for the incorporation
of the nucleoside analogue, 5'-bromodeoxyuridine triphosphate,
with oligo(dT)22 as a primer. The incorporated
5'-bromodeoxyuridine monophosphate product was detected
colorimetrically at 405 nM using alkaline phosphatase-conjugated
anti-bromodeoxyuridine monoclonal antibody and p-nitrophenyl
phosphate substrate after a 1-h incubation.
Analysis of virus proteins.
Lysates from transfected cells
(106 cells per 40 µl) or from cell-free virus resuspended
in protein-denaturing buffer (33) were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis on a 12%
polyacrylamide gel and then were transferred to a nitrocellulose membrane (Amersham) for Western blot analysis. HFV proteins were detected using a 1:100 dilution of anti-HFV human serum and a 1:5,000
dilution of an anti-human immunoglobulin G-alkaline phosphatase conjugate (Serolab) and was developed in a solution containing 0.3 mg
of nitroblue tetrazolium per ml, 0.15 mg of
5-bromo-4-chloro-3-indolylphosphate (BCIP), 100 mM Tris-HCl (pH 9.5),
100 mM NaCl, 5 mM MgCl2, and 1 mM CaCl2 for 5 to 30 min.
 |
RESULTS |
Role of SII in dimer formation.
Previously, the role of SII
(positions 391 to 410 of the viral RNA) in dimer formation had been
investigated in vitro by masking the site with cDNA oligonucleotides
and by introducing mutations into the site (18). In this
study further mutations were introduced into SII (Table 1) to determine
the specific nucleotides involved. When tested for their dimerization
properties in vitro, SIIM1, SIIM2, and SIIM3 resulted in significant
reductions in dimer formation (Fig. 1a,
SIIM1 lanes, SIIM2 lanes, and SIIM3 lanes) compared with the wild-type
RNA (Fig. 1a, first two lanes). SIIM1 disrupts only the end nucleotide
of the palindrome, SIIM2 disrupts most of the palindrome, and SIIM3
increases the size of the existing palindrome. The reduction in
dimerization observed with these 3 mutants confirms the importance of
the palindrome and suggests its size is also critical for dimerization
in vitro. The result seen with SIIM3 is consistent with that seen for
the previously reported M32 (18), which introduced an
extended palindrome of 12 nucleotides.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 1.
Mutations to sequences in and surrounding the palindrome
in SII, as shown by agarose gel electrophoresis. (a) First two lanes,
wild-type (WT) RNA, nucleotides 322 to 480; next two lanes, SIIM1; next
two lanes, SIIM2; next two lanes, SIIM3; next two lanes, SIIM4; next
two lanes, SIIM5. (b) First two lanes, wild-type RNA, nucleotides 322 to 480; next two lanes, SIIM6; next two lanes, SIIM7. The first lane of
each pair contains denatured RNA, the second lane contains native RNA.
The numbers to the left of the gels indicate nucleic acid sizes (in
kilobases). d, dimer; m, monomer.
|
|
However, the mutants SIIM4 and SIIM5, which changed the nucleotides
flanking the palindrome and increased the existing palindrome by two
nucleotides, dimerized to the same extent as the wild-type RNA (Fig.
1a, SIIM4 lanes and SIIM5 lanes), indicating that the sequences
immediately surrounding the palindrome are not important for in vitro
dimerization. Moreover, a moderate increase of the palindrome by two
nucleotides can be tolerated in vitro, in contrast to SIIM3, which
increases the palindrome by six nucleotides and impairs dimerization.
Total disruption of the palindrome, which was caused by SIIM6, or
formation of a new palindromic sequence, which was caused by SIIM7,
inhibited dimer formation (Fig. 1b, SIIM6 lanes and SIIM7 lanes). In
addition, SIIM8 greatly reduced dimerization, forming mainly monomers
(not shown), possibly through destabilization of the dimeric structure.
These results, together with the previously reported results for M32
and M43, demonstrate that the palindrome is the important sequence in
SII, since disruption of this sequence results in a reduction in dimer
formation. The size and nucleotide composition also appear to be
important factors in dimerization. Extension of the palindrome by two
nucleotides, whether by an A/U or a G/C, was tolerated (SIIM4 and
SIIM5), while a longer nucleotide extension (SIIM3 and the previously
reported M32 [18]) was not, indicating a limit to the
size of a tolerated palindromic extension. No shortening of the
palindrome was tolerated (SIIM1).
Role of SI and SIII in dimer formation.
Since SI (positions
348 to 368 of the viral RNA) was shown to affect dimer formation,
mutants were designed to investigate the specific nucleotides involved.
The construct SIM1 was designed to change the last four nucleotides of
SI, which were not part of the PBS. This construct produced an
indeterminate band on the agarose gel, which was halfway between
monomer and dimer (Fig. 2a, third and
fourth lanes). The same result was obtained each time the dimer
experiment was performed (more than four occasions).

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Mutations in SI and SIII, as shown by agarose gel
electrophoresis. (a) First two lanes, wild-type (WT) RNA,
nucleotides 322 to 480; next two lanes, SIM1; next two lanes, SIM2;
next two lanes, SIM3; next two lanes, SIM4; next two lanes, SIM5; next
two lanes, SIM6. (b) First two lanes, wild-type RNA, nucleotides 322 to
480; next two lanes, SIM1; next two lanes, SIM2; next two lanes,
SIIIM1. The first lane of each pair contains denatured RNA, the second
lane contains native RNA. The numbers to the left of the gels indicate
nucleic acid sizes (in kilobases). d, dimer; m, monomer.
|
|
Random nucleotides were introduced into the wild-type sequence from the
end of the PBS in SI (position 365) up to position 380 (between SI and
SII). The resulting HFV construct, SIM2, dimerized efficiently (Fig.
2a, fifth and sixth lanes), suggesting that the nucleotides at the
mutated positions were not involved in HFV dimerization.
It has been proposed previously that G tetrads may play an essential
role in retroviral genomic dimerization (1, 56). Since SI
contained a G tetrad (positions 360 to 363), the mutant SIM3 was
designed, replacing the G tetrad in the PBS with UAAC. This construct
was able to dimerize to wild-type levels (Fig. 2a, seventh and eighth
lanes), indicating that G tetrads are not involved in HFV dimerization
in vitro.
SIM4 contained a deletion from the PBS up to and including the first
nucleotide of the G tetrad (position 360), with the remaining three Gs
changed to AAC, and dimerization was not impaired (Fig. 2a, 9th and
10th lanes). Since SIM4 left the last five nucleotides of SI unchanged,
a construct was designed to change the last four nucleotides of SI,
which were not part of the PBS.
The construct SIM5 contained a deletion from the second nucleotide in
SI up to and including the second nucleotide in the palindrome of SII.
SIM6 contained a deletion from the second G in the G tetrad in SI up to
and including the second nucleotide in the palindrome of SII (position
398), and the G nucleotide at position 360 was replaced by a U. Both
SIM5 and SIM6 were unable to dimerize (Fig. 2a, 11th and 12th lanes for
SIM5, 13th and 14th lanes for SIM6). Since partial deletion of the
palindrome reduced dimerization, some reduction might have been expected.
A third sequence, SIII (441 to 460), was also previously shown to be
involved in HFV RNA dimerization in vitro (18). Two further mutants confirmed that SIII does not contribute to HFV dimerization in vitro. With the mutant SIIIM1, in which all nucleotides in SIII were randomly changed (Table 1), dimerization was only slightly
reduced (Fig. 2b, seventh and eighth lanes). A similar reaction was
obtained with mutant SIIIM2, in which nucleotides in SIII were changed
such that the amino acid sequence remained the same as that of the wild
type (not shown).
The effects of dimer mutants in cell culture.
A selection of
the mutants, which differently affected dimer formation in vitro, was
inserted into the wild-type virus backbone, and each was tested for its
effect on virus replication in cell culture. Of SII, the constructs
SIIM2, SIIM8, and M32 were chosen since they significantly reduced
dimer formation in vitro (Fig. 1a), and the constructs SIIM6 and SIIM7
abolished dimer formation in vitro (Fig. 1b). In contrast, SIIM4 was
chosen because it had no adverse effect on in vitro dimerization (Fig.
1a). Of SI and SIII, the constructs SIIIM2 (slightly reduced dimer
formation in vitro) and SIM1 (intermediate band) were also tested in
cell culture.
Wild-type (pHSRV-2) and mutant DNA were transfected into BHK-21 cells,
and the infection was monitored by light microscopy for syncytium
induction for 14 days. A cytopathic effect was first seen in the
HSRV-2- and SIIM4-infected cultures on day 2 p.t., and by day
10 p.t. all cells in these cultures were clearly infected. Supernatant from each culture was assayed for RT activity (Fig. 3). The mutant SIIM4 and wild-type virus
had similar RT activity profiles. Low RT activity was detected in all
mutants on day 2 p.t. This subsequently declined in SIM1, SIIM7,
SIIM6, SIIM8, M32, and SIIM2. For SIIM6, SIIM7, SIIM8, and M32 no RT
activity above background levels was detected for the remainder of the assay (14 days). However, for SIM1 and SIIIM2 the RT activity increased
on days 9 and 13 p.t., respectively, indicating that these two
mutations were not lethal to the virus (Fig. 3). The slight drop
observed for SIM1 on day 14 p.t. is probably due to cell death in
the aging culture.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of RT levels produced by wild-type (HSRV-2)
and dimer mutants in BHK-21 cells. BHK-21 cells seeded at 2 × 105 on the previous day were transfected with 10 µg of
wild-type HSRV-2 ( ), SIM1 ( ), SIIM2 ( ), SIIM4 ( ), SIIM7
(*), SIIM8 ( ), M32 ( ), or SIIIM2 (x) DNA, and supernatant fluid
was assayed for RT activity up to day 14 p.t. Supernatant from
uninfected cells was also assayed (|). The means ± standard
deviations of quadruplicate determinations for each construct are
shown. OD 405 nM, optical density at 405 nM.
|
|
Extracellular virus titer was assessed on FAB cells. No virus was
detected in all samples on day 3 p.t. or for the mutants SIIM6, SIIM7,
and M32 on days 7 and 14 p.t. A virus titer of 10 was shown for
SIM1 on day 14 p.t., and titers of 102 and
103 were observed for the wild-type virus and SIIM4 on days
7 and 14 p.t., respectively. These results correlated with the RT
activities. The virus titer was not determined for SIIIM2 or SIIM8.
All constructs expressed viral proteins, as assessed by Western
blotting (Fig. 4) (protein expression was
not assessed for the mutants SIIM8 and SIIIM2). However, the relative
levels of each protein compared with that of the wild-type virus were
not quantified. No protein bands were observed with SIIM2, SIIM6, SIIM7, and M32 on days 6 and 14 p.t., correlating with the drop in
RT activity, while some expression was seen for SIM1 on days 6 and
14 p.t. (not shown). Both wild-type virus and the mutant SIIM4
were able to produce proteins throughout the assay (not shown).

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of viral protein expression levels between
wild-type (HSRV-2) and mutants. BHK-21 cells (2 × 105) were transfected with 10 µg of wild-type (HSRV-2) or
mutant DNA. The levels of viral protein expression were assessed on day
2 p.t. by Western blotting using HFV antibody-positive human
serum. The first and last lanes are full-range molecular mass protein
markers.
|
|
Mutants which are affected in dimerization can still package.
To investigate whether those dimerization mutants which failed to
replicate in cell culture were unable to package RNA, RPAs were carried
out. BHK/Bel-1 cells (7) were used, since the presence of
the viral transactivator Tas (Bel-1) allows for a higher yield of viral
antigens after transfection. Wild-type HFV (pHSRV-2) served as a
replication-competent virus, whereas mutants SIM1, SIIM2, and SIIM6
were chosen as examples of replication-incompetent mutants. On
BHK/Bel-1 cells, the replication-incompetent mutants again showed an
initial cytopathic effect which eventually disappeared. In negative
control experiments, BHK/Bel-1 cells were transfected with plasmid
pRR3, which encodes Gag and Pol but lacks the env ORF
(unpublished), ensuring that no virions are released into the
supernatant (2, 50). Two days p.t. the supernatant was harvested and concentrated using Centricon columns and the virus was
pelleted through a 20% sucrose cushion. The pellet was resuspended in
50 µl of H2O, 10 µl of which was used in a Western blot
and the remaining 40 µl of which was used for RPA. The doublet of the
70- and 74-kDa HFV Gag protein was readily observed on Western blots
for all mutants tested, whereas no specific bands were detected for the
negative control (Fig. 5a). Relative band
intensities are also shown on the gel. To investigate whether the
inability to replicate in cell culture was due to a packaging defect,
RPAs were carried out. The antisense probe derived from the
gag ORF detected only the unspliced genomic transcript.
However, the replication-defective mutants were able to package the
viral genome (Fig. 5b). The band intensities (Fig. 5b) indicate the
extent of packaging relative to that of the wild type. Similar results
were obtained when mutants SIM1, SIIM6, and SIIIM2 were tested. As
demonstrated, SIIM6 is replication incompetent in cell culture, whereas
SIM1 and SIIM2 replicate moderately (Fig. 4). These results are in
agreement with Heinkelein et al. (29), who introduced
deletions in the leader region that affected the dimerization sites but
not packaging. Thus, a packaging defect does not underlie the inability
of the dimerization mutants to replicate.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of virions released from wild-type virus
(HSRV-2) and dimerization mutants. BHK/Bel-1 cells were transfected
with 10 µg of the respective DNA, and the virus was pelleted 48 h
later as described in Materials and Methods. (a) RPA of nucleic acid
isolated from virions. The full-length probe and the protected fragment
of 350 and 248 nucleotides (nt), respectively, are shown. The relative
band intensities of each band compared with that of the positive
control HSRV-2, determined using LabImage version 2.51, are shown at
the bottom of the gel. (b) Western blot with foamy virus-infected
antiserum. The 70- and 74-kDa doublet of the Gag protein is indicated.
The relative band intensities of the 70- and 74-kDa Gag doublet
compared with that of the positive control HSRV-2, determined using
LabImage version 2.51, are shown at the bottom of the gel.
|
|
 |
DISCUSSION |
Previously we showed that three sites, SI (348 to
368), SII (391 to 410), and SIII (441 to
460), were required for efficient dimerization of HFV RNA in
vitro (18). In transduction experiments, the region
containing the DLS was found to be important for successful delivery of
HFV-based vectors (19, 28, 58). In the present study the
role of these sites was investigated further by the introduction of
mutations and by testing for their ability to dimerize in vitro.
The palindromic sequence (positions 396 to 405) within SII was shown to
be important, since dimer formation was abolished when it was changed
to a nonpalindromic sequence (SIIM6). Mutations which resulted in a
decreased palindrome (SIIM1 by two nucleotides and SIIM2 by six
nucleotides) or an increased palindrome (SIIM3 by six nucleotides)
reduced dimerization, indicating that the size of the palindrome is
important. This was in agreement with results with the mutant M32,
tested previously, which increased the palindrome by 12 nucleotides
(18). When the nucleotides in the palindrome were changed
to a different palindrome of equal length (SIIM7), again no
dimerization was observed, indicating that the specific nucleotide
composition of the palindrome is important for dimerization in vitro.
However, the nonpalindromic sequences within SII are dispensable for
dimer formation (SIIM4 and SIIM5) but not when they resemble part of
the palindrome (SIIM8). Palindromic sequences have been shown to play a
central role in the dimerization of retroviral RNA, including HIV-1
(34, 54) and MLV (26), in which they are part
of the DLS. Dimerization is thought to be initiated via a loop-loop
interaction through Watson-Crick base pairing of a palindrome to form
an immature kissing-loop structure in HIV-1, avian leukosis-sarcoma
virus, and MLV (22, 23, 34, 36, 54). In the case of HIV-1
and MLV this immature dimer is packaged by the Gag polyprotein.
Following particle release and protein maturation, the nucleocapsid
protein is thought to promote maturation of the dimer into a more
stable structure (20, 24, 25). HIV-1 isolates are able to
tolerate mutations in the palindromic loop that retain a palindromic
sequence (47, 54). Mutations that disrupt the palindrome
generally abolish dimerization in vitro, although some base changes can be tolerated, resulting in reduced dimer formation (12, 47, 54). Nucleotide changes can also be tolerated in the stem
structure, provided that the stem is maintained (47, 54).
The absence of a stem-loop structure for HFV and the lack of tolerance
for nucleotide changes in SII suggest that the mechanism for HFV
dimerization is different from that of HIV.
Other mechanisms proposed to be involved in dimerization include
guanine tetrads (56) and the purine-rich sequence PuGGAPuA through the formation of quartets involving both guanine and adenine bases (41). Subsequent studies argued against this model,
since efficient dimerization still occurs in HIV-1, HIV-2, and bovine leukemia virus mutants lacking these sequences in vitro (4, 30,
54) and for HIV-1 in vivo (6). In contrast,
guanine-rich sequences, in addition to a palindromic sequence, were
found to be important for efficient Moloney murine sarcoma virus
replication (39). The present study demonstrates that the
guanine quartet, within the PBS (positions 364 to 367), in SI is
not involved in HFV dimer formation in vitro, since two mutants (SIM3
and SIM4) in which these nucleotides were changed dimerized at
wild-type levels.
The effect of mutations in SII on virus replication in cell culture
revealed that mutations resulting in dimer reduction in vitro inhibited
virus spread in cell culture, even though the viral proteins (Gag, Tas,
and Bet) were still produced.
Inhibition of virus growth was seen even when only one nucleotide in
the palindrome was changed (SIIM1 and SIIM2) and when the palindrome
was exchanged for a different palindrome of equal length (SIIM7). This
suggests an essential role of the wild-type palindromic sequence,
perhaps in initializing dimer formation. These results, taken together
with the fact that no stem-loop structure was found by using a computer
model, suggest that the mechanism for HFV dimerization is different
from that of HIV-1 for several reasons. First, for HIV-1, mutations
that partially disrupt the stem-loop palindrome can be tolerated by the
virus in cell culture, although in many cases growth is severely
impaired. Moreover, provided that the palindromic sequence is
maintained, replication is delayed but not abrogated (5).
In addition, if SII formed a stem structure, then nucleotide changes in
the sequences surrounding the palindrome would be expected to reduce dimerization and virus replication. This was clearly not the case for
SIIM4, where the mutant replicated at wild-type levels.
The mutations in SIM1 and SIIIM2 were not lethal to the virus, but
replication was slower than it was for the wild-type virus. Sequence
analysis showed that the mutant SIM1 acquired base changes that
restored the wild-type sequence (with the addition of two extra
nucleotides), accounting for the increase in virus replication on day
9 p.t. The four mutated nucleotides in SIM1 were not part of the
PBS, and from these data their role in HFV replication is unclear. If,
as suggested, SII is required to initiate dimer formation, then SI and
SIII may be required to stabilize this complex. This would then explain
why, in contrast to SII mutants which are lethal to the virus, those in
SI and SIII result in slower virus replication, allowing the
nucleotides to revert over time to form a more stable complex.
The results shown here demonstrate that efficient dimerization is a
critical step for HFV to generate infectious virus. Although HFV
virions can contain DNA, the initial nucleic acid packaged is RNA
(2). This packaged RNA is then reverse transcribed
intracellularly into DNA as a late event in the virus life cycle
(42, 61). In contrast to HIV-1 and Moloney murine leukemia
virus, replication-defective HFV dimerization mutants can package
nucleic acid, even though the respective mutants are unable to
replicate in cell culture, suggesting that packaging of genomic RNA is
independent of dimerization. This is supported by the finding that RNA
packaging still occurs after deletion of a large part of the HFV leader
region (29). It remains a possibility that RNA
interactions elsewhere in the genome may have formed dimeric structures
which partly compensated for the loss of the main dimerization sequence.
The finding that dimerization may not be a prerequisite for packaging,
however, is not unique to foamy viruses. Rapid-harvest Rous sarcoma
virus (RSV) and visna virus particles were found to contain
predominately monomeric RNA in early studies, although this may reflect
methods available at the time (9-11). Another possible
explanation for this is that newly packaged dimeric immature RNA is
more unstable in these viruses than that packaged by HIV-1 and MLV
(55). However, analysis of RSV protease mutants which ensure a pure population of immature virions found mainly monomeric RNA
in mutant virions (46). This, taken together with the fact that dimeric RSV RNA has never been isolated from infected cells, suggests that monomeric RNA is encapsidated in RSV and dimerization occurs later (37, 45, 46).
The present study confirmed, by mutational analysis, that SI, SII, and
SIII are involved in the dimerization of HFV RNA, both in vitro and for
the generation of infectious virus in cell culture. However, although
specific sequences were shown to be important for virus replication,
further experiments will be needed to determine the exact nature of the
observed defect. Since dimerization is thought to be involved in
several steps in the HIV-1 and Moloney murine leukemia virus life
cycles, this may also be true of foamy virus dimerization.
 |
ACKNOWLEDGMENTS |
This study was funded by the Wellcome Trust, the Jefferiss Trust,
and the EU.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of G.U.
Medicine and Communicable Diseases, Jefferiss Research Trust
Laboratories, Wright-Fleming Institute, Imperial College School of
Medicine at St. Mary's, London W2 1PG, United Kingdom. Phone: 44 (0)
207 594 3902. Fax: 44 (0) 207 594 3906. E-mail:
m.mcclure{at}ic.ac.uk.
 |
REFERENCES |
| 1.
|
Awang, G., and D. Sen.
1993.
Mode of dimerization of HIV-1 genomic RNA.
Biochemistry
32:11453-11457[CrossRef][Medline].
|
| 2.
|
Baldwin, D. N., and M. I. Linial.
1998.
The roles of Pol and Env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 3.
|
Bender, W.,
Y. H. Chien,
S. Chattopadhyay,
P. K. Vogt,
M. B. Gardner, and N. Davidson.
1978.
High-molecular-weight RNAs of AKR, NZB, and wild mouse viruses and avian reticuloendotheliosis virus all have similar dimer structures.
J. Virol.
25:888-896[Abstract/Free Full Text].
|
| 4.
|
Berkhout, B.,
B. B. Essink, and I. Schoneveld.
1993.
In vitro dimerization of HIV-2 leader RNA in the absence of PuGGAPuA motifs.
FASEB J.
7:181-187[Abstract].
|
| 5.
|
Berkhout, B., and J. L. van Wamel.
1996.
Role of the DIS hairpin in replication of human immunodeficiency virus type 1.
J. Virol.
70:6723-6732[Abstract/Free Full Text].
|
| 6.
|
Berkhout, B.,
A. T. Das, and J. L. van Wamel.
1998.
The native structure of the human immunodeficiency virus type 1 RNA genome is required for the first strand transfer of reverse transcription.
Virology
249:211-218[CrossRef][Medline].
|
| 7.
|
Bieniasz, P. D.,
O. Erlwein,
A. Aguzzi,
A. Rethwilm, and M. O. McClure.
1997.
Gene transfer using replication-defective human foamy virus vectors.
Virology
235:65-72[CrossRef][Medline].
|
| 8.
|
Bieth, E.,
C. Gabus, and J. L. Darlix.
1990.
A study of the dimer formation of Rous sarcoma virus RNA and of its effect on viral protein synthesis in vitro.
Nucleic Acids Res.
18:119-127[Abstract/Free Full Text].
|
| 9.
|
Brachic, M., and R. Vigne.
1975.
Properties of visna virus particles harvested at short time intervals: RNA content, infectivity, and ultrastructure.
J. Virol.
15:1222-1230[Abstract/Free Full Text].
|
| 10.
|
Canaani, E.,
K. V. D. Helm, and P. Duesberg.
1973.
Evidence for the 30-40s RNA as precursor of the 60-70s RNA of Rous sarcoma virus.
Proc. Natl. Acad. Sci. USA
70:401-405[Abstract/Free Full Text].
|
| 11.
|
Cheung, K. S.,
R. E. Smith,
M. P. Stone, and W. K. Joklik.
1972.
Comparison of immature (rapid harvest) and mature Rous sarcoma virus particles.
Virology
50:851-864[CrossRef][Medline].
|
| 12.
|
Clever, J. L.,
M. I. Wong, and T. G. Parslow.
1996.
Requirements for kissing-loop-mediated dimerization of human immunodeficiency virus RNA.
J. Virol.
70:5902-5908[Abstract].
|
| 13.
|
Clever, J. L., and T. G. Parslow.
1997.
Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation.
J. Virol.
71:3407-3414[Abstract].
|
| 14.
|
Darlix, J.,
C. Gabus,
M. T. Nugeyre,
F. Clavel, and F. Barre Sinoussi.
1990.
cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1.
J. Mol. Biol.
216:689-699[CrossRef][Medline].
|
| 15.
|
Elkstrand, D. H. L.,
R. J. K Awad,
C. F. R. Kallander, and J. S. Gronowitz.
1996.
A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation.
Biotechnol. Appl. Biochem.
23:95-105.
|
| 16.
|
Enssle, J.,
I. Jordan,
B. Mauer, and A. Rethwilm.
1996.
Foamy virus reverse transcriptase is expressed independently from the Gag protein.
Proc. Natl. Acad. Sci. USA
93:4137-4141[Abstract/Free Full Text].
|
| 17.
|
Enssle, J.,
A. Moebes,
M. Heinkelein,
M. Panhuysen,
B. Mauer,
M. Schweizer,
D. Neumann Haefelin, and A. Rethwilm.
1999.
An active foamy virus integrase is required for virus replication.
J. Gen. Virol.
80:1445-1452[Abstract].
|
| 18.
|
Erlwein, O.,
D. Cain,
N. Fischer,
A. Rethwilm, and M. O. McClure.
1997.
Identification of the sites that act together to direct dimerisation of human foamy virus RNA in vitro.
Virology
229:251-258[CrossRef][Medline].
|
| 19.
|
Erlwein, O.,
P. D. Bieniasz, and M. O. McClure.
1998.
Sequences in pol are required for transfer of human foamy virus-based vectors.
J. Virol.
72:5510-5516[Abstract/Free Full Text].
|
| 20.
|
Feng, Y. X.,
T. D. Copeland,
L. E. Henderson,
R. J. Gorelick,
W. J. Bosche,
J. G. Levin, and A. Rein.
1996.
HIV-1 nucleocapsid protein induces `maturation' of dimeric retroviral RNA in vitro.
Proc. Natl. Acad. Sci. USA
93:7577-7581[Abstract/Free Full Text].
|
| 21.
|
Fischer, N.,
M. Heinkelein,
D. Lindemann,
J. Enssle,
C. Baum,
E. Werder,
H. Zentgraf,
J. G. Muller, and A. Rethwilm.
1998.
Foamy virus particle formation.
J. Virol.
72:1610-1615[Abstract/Free Full Text].
|
| 22.
|
Fisher, J., and S. P. Goff.
1998.
Mutational analysis of stem-loops in the packaging signal of the Moloney murine leukemia virus.
Virology
244:133-145[CrossRef][Medline].
|
| 23.
|
Fosse, P.,
N. Motte,
A. Roumier,
C. Gabus,
D. Muriaux,
J. L. Darlix, and J. Paoletti.
1996.
A short autocomplementary sequence plays an essential role in avian sarcoma-leukosis virus RNA dimerization.
Biochemistry
35:16601-16609[CrossRef][Medline].
|
| 24.
|
Fu, W., and A. Rein.
1993.
Maturation of dimeric viral RNA of Moloney murine leukemia virus.
J. Virol.
67:5443-5449[Abstract/Free Full Text].
|
| 25.
|
Fu, W.,
R. J. Gorelick, and A. Rein.
1994.
Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions.
J. Virol.
68:5013-5018[Abstract/Free Full Text].
|
| 26.
|
Girard, P. M.,
B. Bonnet Mathoniere,
D. Muriaux, and J. Paoletti.
1995.
A short autocomplementary sequence in the 5' leader region is responsible for dimerization of MoMuLV genomic RNA.
Biochemistry
34:9785-9794[CrossRef][Medline].
|
| 27.
|
Haddrick, M.,
A. L. Lear,
A. J. Cann, and S. Heaphy.
1996.
Evidence that a kissing loop structure facilitates genomic RNA dimerisation in HIV-1.
J. Mol. Biol.
259:58-68[CrossRef][Medline].
|
| 28.
|
Heinkelein, M.,
M. Schmidt,
N. Fischer,
A. Moebes,
D. Lindemann,
J. Enssle, and A. Rethwilm.
1998.
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors.
J. Virol.
72:6307-6314[Abstract/Free Full Text].
|
| 29.
|
Heinkelein, M.,
J. Thurow,
M. Dressler,
H. Imrich,
D. Neumann-Haefelin,
M. O. McClure, and A. Rethwilm.
2000.
Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.
J. Virol.
74:3141-3148[Abstract/Free Full Text].
|
| 30.
|
Katoh, I.,
T. Yasunaga, and Y. Yoshinaka.
1993.
Bovine leukemia virus RNA sequences involved in dimerization and specific gag protein binding: close relation to the packaging sites of avian, murine, and human retroviruses.
J. Virol.
67:1830-1839[Abstract/Free Full Text].
|
| 31.
|
Kozac, M.
1986.
Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.
Cell
44:283-292[CrossRef][Medline].
|
| 32.
|
Kung, H. J.,
S. Hu,
W. Bender,
J. M. Bailey,
N. Davidson,
M. O. Nicolson, and R. M. McAllister.
1976.
RD-114, baboon, and woolly monkey viral RNAs compared in size and structure.
Cell
7:609-620[CrossRef][Medline].
|
| 33.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 34.
|
Laughrea, M., and L. Jette.
1994.
A 19-nucleotide sequence upstream of the 5' major splice donor is part of the dimerization domain of human immunodeficiency virus 1 genomic RNA.
Biochemistry
15:13464-13474.
|
| 35.
|
Laughrea, M., and L. Jette.
1997.
HIV-1 genome dimerization: kissing-loop hairpin dictates whether nucleotides downstream of the 5' splice junction contribute to loose and tight dimerization of human immunodeficiency virus RNA.
Biochemistry
36:9501-9508[CrossRef][Medline].
|
| 36.
|
Laughrea, M.,
L. Jette,
J. Mak,
L. Kleiman,
C. Liang, and M. A. Wainberg.
1997.
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization.
J. Virol.
71:3397-3406[Abstract].
|
| 37.
|
Lear, A. L.,
M. Haddrick, and S. Heaphy.
1995.
A study of the dimerization of Rous sarcoma virus RNA in vitro and in vivo.
Virology
212:47-57[CrossRef][Medline].
|
| 38.
|
Linial, M. L.
1999.
Foamy viruses are unconventional retroviruses.
J. Virol.
73:1747-1755[Free Full Text].
|
| 39.
|
Ly, H.,
D. P. Nierlich,
J. C. Olsen, and A. H. Kaplan.
1999.
Moloney murine sarcoma virus genomic RNAs dimerize via a two-step process: a concentration-dependent kissing-loop interaction is driven by initial contact between consecutive guanines.
J. Virol.
73:7255-7261[Abstract/Free Full Text].
|
| 40.
|
Malmesten, A.,
D. H. L. Elkstrand,
L. Akerbolm,
J. S. Gronowitz,
C. F. R. Kallander,
M. Bendinelli, and D. Matteucci.
1998.
A colorimetric reverse transcriptase (RT) assay optimised for Moloney murine leukemia virus, and its use for characterization of RTs of unknown identity.
J. Virol. Methods
75:9-20[CrossRef][Medline].
|
| 41.
|
Marquet, R.,
F. Baudin,
C. Gabus,
J. L. Darlix,
M. Mougel,
C. Ehresmann, and B. Ehresmann.
1991.
Dimerization of human immunodeficiency virus (type 1) RNA: stimulation by cations and possible mechanism.
Nucleic Acids Res.
19:2349-2357[Abstract/Free Full Text].
|
| 42.
|
Moebes, A.,
J. Enssle,
P. D. Bieniasz,
M. Heinkelein,
D. Lindemann,
M. Bock,
M. O. McClure, and A. Rethwilm.
1997.
Human foamy virus reverse transcription that occurs late in the viral replication cycle.
J. Virol.
71:7305-7311[Abstract].
|
| 43.
|
Mougel, M.,
Y. Zhang, and E. Barklis.
1996.
cis-active structural motifs involved in specific encapsidation of Moloney murine leukemia virus RNA.
J. Virol.
70:5043-5050[Abstract/Free Full Text].
|
| 44.
|
Murti, K. G.,
M. Bondurant, and A. Tereba.
1981.
Secondary structural features in the 70S RNAs of Moloney murine leukemia and Rous sarcoma viruses as observed by electron microscopy.
J. Virol.
37:411-419[Abstract/Free Full Text].
|
| 45.
|
Oertle, S., and P. F. Spahr.
1990.
Role of the Gag polyprotein precursor in packaging and maturation of Rous sarcoma virus genomic RNA.
J. Virol.
64:5757-5763[Abstract/Free Full Text].
|
| 46.
|
Ortiz-Conde, B. A., and S. H. Hughes.
1999.
Studies of the genomic RNA of leukosis viruses: implications for RNA dimerization.
J. Virol.
73:7165-7174[Abstract/Free Full Text].
|
| 47.
|
Paillart, D. C.,
R. Marquet,
E. Skripkin,
B. Ehresmann, and C. Ehresmann.
1994.
Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA.
J. Biol. Chem.
269:27486-27493[Abstract/Free Full Text].
|
| 48.
|
Paillart, J. C.,
L. Berthoux,
M. Ottmann,
J. L. Darlix,
R. Marquet,
B. Ehresmann, and C. Ehresmann.
1996.
A dual role of the putative RNA dimerization initiation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis.
J. Virol.
70:8348-8354[Abstract].
|
| 49.
|
Paillart, J. C.,
R. Marquet,
E. Skripkin,
C. Ehresmann, and B. Ehresmann.
1996.
Dimerization of retroviral genomic RNAs: structural and functional implications.
Biochimie
78:639-653[Medline].
|
| 50.
|
Pietschmann, T.,
M. Heinkelein,
M. Heldmann,
H. Zentgraf,
A. Rethwilm, and D. Lindemann.
1999.
Foamy virus capsids require the cognate envelope protein for particle release.
J. Virol.
73:2613-2621[Abstract/Free Full Text].
|
| 51.
|
Prats, A. C.,
C. Roy,
P. A. Wang,
M. Erard,
V. Housset,
C. Gabus,
C. Paoletti, and J. L. Darlix.
1990.
cis elements and trans-acting factors involved in dimer formation of murine leukemia virus RNA.
J. Virol.
64:774-783[Abstract/Free Full Text].
|
| 52.
|
Rethwilm, A.,
G. Baunach,
K. O. Netzer,
B. Maurer,
B. Borisch, and V. ter Meulen.
1990.
Infectious DNA of the human spumaretrovirus.
Nucleic Acids Res.
18:733-738[Abstract/Free Full Text].
|
| 53.
|
Rethwilm, A.
1995.
Regulation of foamy virus gene expression.
Curr. Top. Microbiol. Immunol.
193:1-23[Medline].
|
| 54.
|
Skripkin, E.,
J. C. Paillart,
R. Marquet,
B. Ehresmann, and C. Ehresmann.
1994.
Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro.
Proc. Natl. Acad. Sci. USA
91:4945-4949[Abstract/Free Full Text].
|
| 55.
|
Stolfus, C. M., and P. N. Snyder.
1975.
Structure of the B77 sarcoma virus RNA: stabilization of RNA after packaging.
J. Virol.
16:1161-1170[Abstract/Free Full Text].
|
| 56.
|
Sundquist, W. I., and S. Heaphy.
1993.
Evidence for interstrand quadruplex formation in the dimerization of human immunodeficiency virus 1 genomic RNA.
Proc. Natl. Acad. Sci. USA
15:3393-3397.
|
| 57.
|
Vagner, S.,
A. Waysbort,
M. Marenda,
M. C. Gensac,
F. Amalric, and A. C. Prats.
1995.
Alternative translation of the Moloney murine leukemia virus mRNA controlled by internal ribosomal entry involving the p57/PTB splicing factor.
J. Biol. Chem.
270:20376-20383[Abstract/Free Full Text].
|
| 58.
|
Wu, M.,
S. Chari,
T. Yanchis, and A. Mergia.
1998.
cis-acting sequences required for simian foamy virus type 1 vectors.
J. Virol.
72:3451-3454[Abstract/Free Full Text].
|
| 59.
|
Yu, S. F., and M. L. Linial.
1993.
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.
J. Virol.
67:6618-6624[Abstract/Free Full Text].
|
| 60.
|
Yu, S. F.,
D. N. Baldwin,
S. R. Gwynn,
S. Yendapalli, and M. L. Linial.
1996.
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.
Science
271:1579-1582[Abstract].
|
| 61.
|
Yu, S. F.,
M. D. Sullivan, and M. L. Linial.
1999.
Evidence that the human foamy virus genome is DNA.
J. Virol.
73:1565-1572[Abstract/Free Full Text].
|
Journal of Virology, April 2001, p. 3731-3739, Vol. 75, No. 8
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3731-3739.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chew, D. S. H., Choi, K. P., Heidner, H., Leung, M.-Y.
(2004). Palindromes in SARS and Other Coronaviruses. INFORMS Journal on Computing
16: 331-340
[Abstract]
-
Verschoor, E. J., Langenhuijzen, S., van den Engel, S., Niphuis, H., Warren, K. S., Heeney, J. L.
(2003). Structural and Evolutionary Analysis of an Orangutan Foamy Virus. J. Virol.
77: 8584-8587
[Abstract]
[Full Text]
-
Dirac, A. M. G., Huthoff, H., Kjems, J., Berkhout, B.
(2001). The Dimer Initiation Site Hairpin Mediates Dimerization of the Human Immunodeficiency Virus, Type 2 RNA Genome. J. Biol. Chem.
276: 32345-32352
[Abstract]
[Full Text]